logo

DermNet NZ

Invitation to complete acne survey

Facts about the skin from DermNet New Zealand Trust. Topic index: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Rifampicin

Rifampicin is an antibiotic used to treat serious bacterial infections. It may be prescribed by dermatologists for the treatment of:

It is also used to treat brucellosis, serious staphylococcal infections and to clear asymptomatic carriers of Neisseria meningiditis (which can cause meningococcal disease).

Rifampicin is active against a variety of organisms including Staphylococcus aureus, Staphylococcus epidermidis, Mycobacterium tuberculosis, Mycobacterium leprae, Neisseria meningiditis and Brucella species.

It should always be prescribed with another antibiotic, in order to prevent bacterial resistance, which can develop rapidly if it is used alone.

It should be taken on an empty stomach at least 30 minutes before a meal or 2 hours after a meal. Antacids should be given at least 1 hour after rifampicin.

In New Zealand rifampicin is available as:

Side effects

Rifampicin is usually well tolerated and rarely causes serious toxicity. The commonest side effects involve skin and the gastrointestinal system.

Discoloured urine on rifampicin
Discoloured urine while on rifampicin
Bodily fluids
Tears, sweat and urine may become orange coloured and contact lenses may be permanently stained.
Skin
Usually mild and self-limiting flushing and itching with or without rash. Hives are uncommon. Erythema multiforme and toxic epidermal necrolysis have rarely been reported.
Gastrointestinal
Loss of appetite, vomiting, abdominal pain and diarrhoea.
Liver
Hepatitis, particularly if rifampicin is given with isoniazid
Blood
Thrombocytopaenia (low platelets potentially resulting in bruising and bleeding), rarely low white blood cell count and disseminated intravascular coagulation, and very rarely agranulocytosis (severely decreased white blood cell counts).
Musculoskeletal
Muscle weakness and myopathy are uncommon

Rifampicin is sometimes used intermittently (less than 2 to 3 doses per week) for the treatment of tuberculosis and leprosy. When rifampicin is used in this way, it may be associated with a ‘flu-like syndrome, shortness of breath, low blood pressure, acute renal failure and shock.

Drug interactions

Rifampicin is a P-glycoprotein inducer and may increase the breakdown of other medications, making them less effective. The dosage of these drugs may need adjustment if taken together with rifampicin:

Precautions

Related information

References

On DermNet NZ:

Other websites:

Books about skin diseases:

See the DermNet NZ bookstore

Author: Weng Chyn Chan MB ChB, Dept of Dermatology Health Waikato

Note:

The New Zealand approved datasheet is the official source of information for this prescription medicine, including approved uses and risk information. Check the New Zealand datasheet on the Medsafe website.

DermNet NZ does not provide an online consultation service.
If you have any concerns with your skin or its treatment, see a dermatologist for advice.